Genmab (GMAB) return on invested capital (ROIC)

Return on invested capital · fiscal 2025
10.5%

Genmab (GMAB) earned a return on invested capital of 10.5% in fiscal 2025 (the year ended December 31, 2025). That is 26.8 percentage points lower than the 37.3% of fiscal 2024. Figures as of 18 Nov 2026, 01:41 UTC, from Yahoo Finance.

Key facts

Return on invested capital, fiscal 2025
10.5%
Change on fiscal 2024
−26.8 pts
Highest on record
94.6%fiscal 2023
Lowest on record
10.5%fiscal 2025
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Genmab return on invested capital (ROIC), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 94.6% in fiscal 2023 and the lowest 10.5% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is 88.6%.

History · 4 fiscal years

Return on invested capital by fiscal year

Genmab return on invested capital (ROIC), year by year

Genmab (GMAB) return on invested capital (ROIC) by fiscal year
Fiscal yearReturn on invested capitalChangeYear ended
202510.5% 26.8 pts down
202437.3% 57.4 pts down
202394.6% 6.1 pts up
202288.6%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

How to read it

It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.

Return on invested capital at health care companies of similar size

Return on invested capital of Genmab and comparable companies
CompanyReturn on invested capitalFiscal year
Mettler-Toledo International MTD45.0%2025
Centene CNC-1.4%2025
Genmab GMAB10.5%2025
ResMed RMD25.5%2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on GMAB

Genmab, figure by figure

Genmab (GMAB) overview: price, valuation and scorecardAll health care companies by market value

Genmab return on invested capital (ROIC): questions and answers

What is Genmab's return on invested capital?

Genmab (GMAB) earned a return on invested capital of 10.5% in fiscal 2025 (the year ended December 31, 2025). That is 26.8 percentage points lower than the 37.3% of fiscal 2024.

Is Genmab's return on invested capital high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is 88.6%.

What are the highest and lowest return on invested capital figures on record for Genmab?

Across the 4 fiscal years on record (2022–2025), the highest was 94.6% in fiscal 2023 and the lowest 10.5% in fiscal 2025.

How is Genmab's return on invested capital calculated?

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Genmab (GMAB) return on invested capital (ROIC)”, data as of 18 November 2026. https://funkfolio.com/stock/GMAB/roic

Underlying data: Yahoo Finance.